Novo Nordisk A/S (NYSE:NVO) has partnered with Anthropic to use Claude models and Claude Science in its research and development workflows, with the initial focus on specific scientific problems where AI can have the greatest impact. Novo will also use Anthropic’s frontier models for AI-driven software development. Reuters reported that Novo already uses Claude to automate clinical-trial report generation, cutting patient-documentation timelines from months to minutes.
The partnership comes as Novo tries to strengthen its pipeline amid increasing competition in obesity drugs. The company’s Q2 adjusted sales rose 7% at constant exchange rates to DKK 78.5 billion, while adjusted operating profit increased 11% to DKK 33.4 billion. At the same time, Novo recorded DKK 6.3 billion in non-cash impairments on pipeline assets, including DKK 4 billion related to monlunabant, underscoring the importance of improving R&D productivity and pipeline outcomes.
AI Could Help Novo Nordisk Accelerate its Next Wave of Drugs
The biggest potential benefit is a faster and more productive R&D engine. If Claude can reduce the time scientists spend on data analysis, documentation, biological reasoning, and other research workflows, Novo Nordisk A/S could potentially move candidates through discovery and development more efficiently. The fact that Claude has already reduced certain documentation processes from months to minutes provides an early operational example, although it does not yet establish a financial benefit at the drug-development level.
The timing is particularly relevant because Novo needs stronger pipeline productivity. Reuters reported that the company recently faced investor concerns over CagriSema’s trial performance and the slower-than-expected launch of the Wegovy pill. Novo is also competing against Eli Lilly in an obesity market that Reuters said could exceed $100 billion annually by 2030. Faster identification and development of differentiated medicines could therefore help Novo replenish growth beyond its existing semaglutide franchise.
The Anthropic deal also expands an AI strategy that already includes partnerships with OpenAI and Amazon Web Services. Novo said its AWS collaboration is designed to compress the path from drug target to first human dose, while its OpenAI partnership applies AI across drug discovery and commercial operations. Adding Claude gives Novo another advanced AI platform within a broader effort to make R&D more technology-driven.
Novo Nordisk’s AI Push Has Yet to Prove Its Financial Value
The immediate financial impact remains uncertain because Novo Nordisk A/S and Anthropic have not disclosed specific drug targets, development milestones, financial terms, or expected cost savings. The current arrangement begins with testing Claude in selected workflows, meaning the partnership has not yet demonstrated that AI will materially increase successful drug approvals, revenue, or free cash flow. Reuters specifically described the initial applications as testing and targeted workflow development.
There is also a risk that faster research does not translate into better medicines. Novo Nordisk A/S’s DKK 6.3 billion Q2 impairment on pipeline assets illustrates that substantial R&D spending can still produce disappointing outcomes. AI may accelerate analysis and administrative work, but clinical validation, regulatory requirements, and biological uncertainty remain major constraints on drug development.
Competitive pressure is another consideration. Major pharmaceutical companies are increasingly adopting AI, so Claude may improve Novo’s efficiency without creating a durable competitive advantage. Meanwhile, Novo continues to face pressure from Lilly in obesity treatments; Reuters reported that Lilly’s oral obesity drug had already captured more than 30% of new U.S. oral-weight-loss patients by September, while Novo’s Wegovy pill had held an estimated 90% share as of August.
Conclusion
The Anthropic partnership strengthens Novo Nordisk A/S’s effort to improve R&D productivity at a time when pipeline execution has become increasingly important. Existing Claude applications already show meaningful time savings in clinical documentation, while the broader AI strategy could eventually lower development costs and accelerate new-product launches. Still, the financial payoff remains unproven, and AI cannot eliminate clinical failure or competitive pressure. For Novo, the partnership is therefore primarily a potential pipeline and productivity catalyst rather than an immediate earnings driver.
READ NEXT: McCormick-Unilever Food Deal Faces UK Competition Review: What it Means for Investors and Haleon Turns to Weight-Loss Drug Users for its Next U.S. Growth Opportunity
This article is originally published at Insider Monkey.
